Clinical Use of PET/MR in Oncology: An Update
Robert Seifert(University Hospital Münster), Lale Umutlu(Essen University Hospital), Marcel Opitz(Essen University Hospital), Benedikt M. Schaarschmidt(Essen University Hospital), Onofrio A. Catalano(Harvard University), Christoph Rischpler(Essen University Hospital), David Kersting(West German Heart and Vascular Center Essen), Kim M. Pabst(West German Heart and Vascular Center Essen), Johannes Grueneisen(Ihre-Radiologen), Christina Laschinsky(Essen University Hospital), Julian Kirchner(Düsseldorf University Hospital), Ilektra-Antonia Mavroeidi(Essen University Hospital), Ken Herrmann(Essen University Hospital)
Cited by 43
Related Papers
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464
Radiotheranostics: a roadmap for future development
|The Lancet Oncology|2020|306
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
|European Journal of Cancer|2023|156
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
|Clinical Cancer Research|2022|145